This evening, @AstraZenecaUS held a fascinating Twitter chat (hashtag #RxSave). The focus of the discussion was on pharma-sponsored prescription savings plans. AZ was also looking for advice on how to…
There has been a lot of commentary this week on Pfizer's announcement that their highly respected research center in Sandwich, UK, will be closed. The original press release suggested that…
There is a lot of good commentary and analysis of last week's JP Morgan Healthcare conference, most notably here, here, and here. Here are a few of our thoughts as…
In our meetings and informal discussions, there were three items we heard again and again: 1. Last year was a terrible fund raising year from a VC-backed company perspective. 2.…
The past few months have seen a number of reports describing how national governments are using policy to spur local pharmaceutical industry growth. We have already described examples from Brazil,…
Earlier this week we wrote about the emerging trend of increasing state government involvement in the pharmaceutical industry. Today we learn about what the government in Brazil is doing. Of…
Like many of you, we are already scheduling meetings at the annual JP Morgan Healthcare Conference in San Francisco in January. This is an invitation-only event, but that doesn't stop…
Our good friends at Drug Delivery Technology have, as of January, changed the name of their publication to Drug Development and Delivery. Why is this significant? We think that drug…
Last week we wrote about the Russian government's desire to grow their national pharmaceutical infrastructure. Our reading of the situation is that the government will "suggest" that ex-Russia companies who…
Here is a sample of announcements from today alone regarding the pharmaceutical industry in India: First, UK-based Reckitt Benckiser is acquiring Paras Pharmaceuticals for $726 million. Paras makes a variety…